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Rapid progress has been made in obtaining an 
inventory of Parkinson’s Disease (PD) associated genes. 
The challenge now is to understand their interactions and 
on which physiological pathways they converge. Two 
major themes have emerged; influence upon mitochondrial 
dynamics and on trafficking within the endocytic pathway 
[1]. Parkin (PARK2) is a ubiquitin E3-ligase, for which loss 
of function mutations lead to PD. Under basal conditions 
Parkin is largely held in an inactive state. It is recruited 
to mitochondria by another PD linked protein, the kinase 
PINK1, which specifically accumulates on depolarised 
mitochondria. Parkin then promotes mitophagy by 
ubiquitylating multiple mitochondrial proteins [2]. The 
rapid and dazzling progress in understanding this coupled 
recruitment and phosphorylation-dependent activation 
process has understandably taken centre stage. However, 
there remains no formal proof that defects in mitophagy 
lead to PD. Most cellular studies of mitophagy rely upon 
Parkin over-expression. Irrespective of this matter, it has 
become clear that Parkin may play more widespread roles 
that are associated with alternative pathophysiology. 
Broader links between Parkin and mitochondrial 
health have been made in both cardiac maturation and 
following myocardial infarction [3]. Parkin knock-
out mice placed on a high fat diet resist weight gain, 
steatohepatitis and insulin resistance. They also show 
increased susceptibility to Tuberculosis infection through 
a defect in xenophagy. Parkin is also an important tumour 
suppressor. Decreased PARK2 mRNA or focal deletions 
are found in more than a third of human cancers. This has 
been attributed to diminished ATP levels and increased 
ROS production leading indirectly to inactivation of 
PTEN [4]. Mutations in the same amino acid are found in 
cancer and PD.
Discovery-based proteomic approaches offer 
the opportunity to identify E3-ligase substrates in an 
unbiased manner. Quantitation of protein levels may 
reflect differences in turnover rate but can also report 
indirect effects on transcription/translation. Alternatively 
ubiquitylated peptides can be directly detected by a 
signature diGly modification following trypsinisation. 
We have recently used an alternative method (BioUb) 
whereby a tagged form of ubiquitin is stably expressed 
and biotinylated in vivo. Ubiquitylated proteins from mice, 
flies or human cells can then be isolated by Neutravidin 
beads under stringent washing conditions. This provides 
greater peptide coverage of substrates although the actual 
site of ubiquitylation is not always identified [5].
Acute mitochondrial depolarisation provides the 
only known trigger for Parkin activation and therefore 
offers a means to facilitate the identification of substrates. 
Using this procedure in tissue cell culture models has 
revealed a broad swathe of mitochondrial substrates, with 
some bias towards modification with ubiquitin chains 
linked through Lys6 [6]. The overall picture is that a 
distributed ubiquitin signal across the mitochondrial 
surface comprised of many substrate proteins is sufficient 
for Parkin-dependent mitophagy. There remains a need 
to identify Parkin substrates under more physiological 
conditions. Comparative proteomic studies of Parkin 
-/- vs wild type mice and fly brains have reported some 
differentially expressed proteins. However, these reports 
largely pre-date a step change in proteomics technology, 
that increases protein coverage by an order of magnitude. 
We have recently used the BioUb method to search for 
Parkin substrates in a fly model, that compares neuronal 
cells expressing either wild type Parkin or a ligase 
dead mutant [7]. Our results come with the caveat of 
over-expression but do not rely upon any acute drug 
treatments. Of >1000 proteins that were quantitated, 35 
were identified as potential Parkin substrates. Some of 
these were mitochondrial proteins that had been identified 
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Figure 1: Pathophysiologies relevant to Parkin 
function and unbiased proteomic strategies aimed at 
substrate identification in different systems.
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in previous studies, whilst others have been associated 
with the endosomal pathway, including multiple subunits 
of the vacuolar ATPase and components of the Endosomal 
Sorting Complex Required for Transport (ESCRT) 
machinery, ALiX and Vps4. One substrate, the retromer 
component Vps35, mediates trafficking from endosomal 
compartments to the Golgi and the plasma membrane. It is 
itself a PD associated gene that shows genetic interaction 
with Parkin in a fly model [8].
Interest in Parkin function is clearly broadening and 
unbiased proteomics screens offer opportunities to open 
up new biology. Methods have been developed to detect 
direct substrates and advances in label-free proteomics 
offer opportunities for tissue wide analyses. Looking 
forward, these might have less specific emphasis on the 
brain as the relevance to other types of pathophysiology 
is now clear.
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